A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

Jonathan Mannion, Valentina Gifford, Benjamin Bellenie, Winnie Fernando, Laura Ramos Garcia, Rebecca Wilson, Sidonie Wicky John, Savita Udainiya, Emmanuel C. Patin, Crescens Tiu, Angel Smith, Maria Goicoechea, Andrew Craxton, Nathalia Moraes de Vasconcelos, Naomi Guppy, Kwai-Ming J. Cheung, Nicholas J. Cundy, Olivier Pierrat, Alfie Brennan, Theodoros I. Roumeliotis, Graeme Benstead-Hume, John Alexander, Gareth Muirhead, Scott Layzell, Wenxin Lyu, Victoria Roulstone, Mark Allen, Holly Baldock, Arnaud Legrand, Florian Gabel, Natalia Serrano-Aparicio, Chris Starling, Hongyan Guo, Jason Upton, Mads Gyrd-Hansen, Marion MacFarlane, Benedict Seddon, Florence Raynaud, Ioannis Roxanis, Kevin Harrington, Syed Haider, Jyoti S. Choudhary, Swen Hoelder, Tencho Tenev, Pascal Meier

Open source

DOI: 10.1016/j.immuni.2024.04.025
Published: 2024-07
Container: Immunity
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.immuni.2024.04.025,
  title = {A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death},
  author = {Jonathan Mannion and Valentina Gifford and Benjamin Bellenie and Winnie Fernando and Laura Ramos Garcia and Rebecca Wilson and Sidonie Wicky John and Savita Udainiya and Emmanuel C. Patin and Crescens Tiu and Angel Smith and Maria Goicoechea and Andrew Craxton and Nathalia Moraes de Vasconcelos and Naomi Guppy and Kwai-Ming J. Cheung and Nicholas J. Cundy and Olivier Pierrat and Alfie Brennan and Theodoros I. Roumeliotis and Graeme Benstead-Hume and John Alexander and Gareth Muirhead and Scott Layzell and Wenxin Lyu and Victoria Roulstone and Mark Allen and Holly Baldock and Arnaud Legrand and Florian Gabel and Natalia Serrano-Aparicio and Chris Starling and Hongyan Guo and Jason Upton and Mads Gyrd-Hansen and Marion MacFarlane and Benedict Seddon and Florence Raynaud and Ioannis Roxanis and Kevin Harrington and Syed Haider and Jyoti S. Choudhary and Swen Hoelder and Tencho Tenev and Pascal Meier},
  year = {2024},
  journal = {Immunity},
  doi = {10.1016/j.immuni.2024.04.025},
  url = {https://doi.org/10.1016/j.immuni.2024.04.025}
}

RIS

TY  - JOUR
TI  - A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death
AU  - Jonathan Mannion
AU  - Valentina Gifford
AU  - Benjamin Bellenie
AU  - Winnie Fernando
AU  - Laura Ramos Garcia
AU  - Rebecca Wilson
AU  - Sidonie Wicky John
AU  - Savita Udainiya
AU  - Emmanuel C. Patin
AU  - Crescens Tiu
AU  - Angel Smith
AU  - Maria Goicoechea
AU  - Andrew Craxton
AU  - Nathalia Moraes de Vasconcelos
AU  - Naomi Guppy
AU  - Kwai-Ming J. Cheung
AU  - Nicholas J. Cundy
AU  - Olivier Pierrat
AU  - Alfie Brennan
AU  - Theodoros I. Roumeliotis
AU  - Graeme Benstead-Hume
AU  - John Alexander
AU  - Gareth Muirhead
AU  - Scott Layzell
AU  - Wenxin Lyu
AU  - Victoria Roulstone
AU  - Mark Allen
AU  - Holly Baldock
AU  - Arnaud Legrand
AU  - Florian Gabel
AU  - Natalia Serrano-Aparicio
AU  - Chris Starling
AU  - Hongyan Guo
AU  - Jason Upton
AU  - Mads Gyrd-Hansen
AU  - Marion MacFarlane
AU  - Benedict Seddon
AU  - Florence Raynaud
AU  - Ioannis Roxanis
AU  - Kevin Harrington
AU  - Syed Haider
AU  - Jyoti S. Choudhary
AU  - Swen Hoelder
AU  - Tencho Tenev
AU  - Pascal Meier
PY  - 2024
JO  - Immunity
DO  - 10.1016/j.immuni.2024.04.025
UR  - https://doi.org/10.1016/j.immuni.2024.04.025
ER  -

APA

Mannion, J., Gifford, V., Bellenie, B., Fernando, W., Garcia, L. R., Wilson, R., John, S. W., Udainiya, S., Patin, E. C., Tiu, C., Smith, A., Goicoechea, M., Craxton, A., Vasconcelos, N. M. D., Guppy, N., Cheung, K. J., Cundy, N. J., Pierrat, O., Brennan, A., Roumeliotis, T. I., Benstead-Hume, G., Alexander, J., Muirhead, G., Layzell, S., Lyu, W., Roulstone, V., Allen, M., Baldock, H., Legrand, A., Gabel, F., Serrano-Aparicio, N., Starling, C., Guo, H., Upton, J., Gyrd-Hansen, M., MacFarlane, M., Seddon, B., Raynaud, F., Roxanis, I., Harrington, K., Haider, S., Choudhary, J. S., Hoelder, S., Tenev, T., & Meier, P. (2024). A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity. https://doi.org/10.1016/j.immuni.2024.04.025

Source records

crossref · retrieved 2026-09-25T04:18:15.898Z